ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

triptorelin

Also written as “Triptorelin embonate 22.5 mg”, “Triptorelin (Decapeptyl®)” and “Decapeptyl® SR 22.5mg”.

Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Ovarian Hyperstimulation Syndrome, led by 5 companies.

Drug pageTriptorelin: every studyMany companies study it; this page follows only the 20 they lead. All 102 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 23, 201220 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ipsenits history only130 open or runningphase 4since Aug 23, 2012Dec 21, 2006none ahead
Debiopharmits history only30 open or runningphase 3since Sep 11, 2008Sep 11, 2008none ahead
Foresee Pharmaceuticals20 open or runningphase 3since Jan 22, 2025Jan 22, 2025none ahead
AbbVieits history only10 open or runningphase 4since Jul 9, 2010Jul 9, 2010none ahead
Pharmatechits history only10 open or runningphase 4since May 8, 2012May 8, 2012none ahead

Also a collaborator on its studies: QPS and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Foresee Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 22, 2025First studies: 2 phase 3 studies in Prostatic NeoplasmsFirst studyNCT06795191, NCT06795178

TargetBeta

GNRH1 →GNRHR →read by rule
“A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH)”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
GoserelinruleAstraZenecaphase 414

Studies

All 2 Foresee Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06795191Prostatic Neoplasms3WithdrawnNov 30, 20270
NCT06795178Prostatic Neoplasms3WithdrawnDec 31, 20270

How it is read

Names in the registry

  • “Triptorelin embonate 22.5 mg”, 2 entries
  • “Triptorelin (Decapeptyl®)”, 2 entries
  • “Decapeptyl® SR 22.5mg”, 1 entry
  • “Triptorelin Mesylate”, 1 entry
  • “FP-014”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.